International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 088-096
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Oncological Outcomes of Stage IIIA Endometrioid Type Endometrial Cancer: A Multicenter Study
Hanifi SAHIN1, Ibrahim YALCIN2, Mustafa Erkan SARI2, Eda Adeviye SAHIN1, Koray ASLAN2, Ozgur AGLAMIS3, Varol GULSEREN4, Kemal GUNGORDUK5, Mehmet Mutlu MEYDANLI2, Ali AYHAN6
1Department of Gynecologic Oncology, Malatya Education and Research Hospital, Malatya, TURKEY
2University of Health Sciences, Faculty of Medicine, Zekai Tahir Burak Women’s Health Training and Research Hospital, Department of Gynecologic Oncology, Ankara, TURKEY
3Cerkezkoy Public Hospital, Department of Gynecology, Tekirdag, TURKEY
4Mersin State Hospital, Department of Gynecology, Mersin, TURKEY
5Mugla Education and Research Hospital, Department of Gynecologic Oncology, Mugla, TURKEY
6Baskent University, Faculty of Medicine, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ankara, TURKEY
Keywords: Endometrial cancer, Stage IIIA, Prognostic factor
The objective of this retrospective study was to evaluate Stage IIIA endometrioid type endometrial carcinomas (ECCs) and to analyze clinical and pathological determinants of prognosis in three tertiary hospitals between January 2007 and January 2017. Forty-seven patients with a median age of 61 (range: 31 to 76) years were diagnosed with Stage IIIA disease. Median follow-up was 45 (range: 6 to 116) months. The five-year disease-free survival (DFS) rate was 57.2%, and the overall survival (OS) rate was 59.7%. In the univariate analysis, age and grade of the disease (1-2 versus 3) disease were found to be significant factors for DFS. Univariate analysis also revealed the presence of cervical stromal involvement and grade of the disease were associated with decreased OS. In the multivariate analysis, however, only patients with an advanced histological grade had a reduced risk for OS (hazard ratio [HR] 2.9; 95% confidence interval [CI] 1.020-8.615; p= 0.040). In conclusion, histological grade seems to be an independent prognostic factor for OS in patients with Stage IIIA ECCs.
Hanifi SAHIN1, Ibrahim YALCIN2, Mustafa Erkan SARI2, Eda Adeviye SAHIN1, Koray ASLAN2, Ozgur AGLAMIS3, Varol GULSEREN4, Kemal GUNGORDUK5, Mehmet Mutlu MEYDANLI2, Ali AYHAN6
1Department of Gynecologic Oncology, Malatya Education and Research Hospital, Malatya, TURKEY
2University of Health Sciences, Faculty of Medicine, Zekai Tahir Burak Women’s Health Training and Research Hospital, Department of Gynecologic Oncology, Ankara, TURKEY
3Cerkezkoy Public Hospital, Department of Gynecology, Tekirdag, TURKEY
4Mersin State Hospital, Department of Gynecology, Mersin, TURKEY
5Mugla Education and Research Hospital, Department of Gynecologic Oncology, Mugla, TURKEY
6Baskent University, Faculty of Medicine, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ankara, TURKEY
Keywords: Endometrial cancer, Stage IIIA, Prognostic factor
The objective of this retrospective study was to evaluate Stage IIIA endometrioid type endometrial carcinomas (ECCs) and to analyze clinical and pathological determinants of prognosis in three tertiary hospitals between January 2007 and January 2017. Forty-seven patients with a median age of 61 (range: 31 to 76) years were diagnosed with Stage IIIA disease. Median follow-up was 45 (range: 6 to 116) months. The five-year disease-free survival (DFS) rate was 57.2%, and the overall survival (OS) rate was 59.7%. In the univariate analysis, age and grade of the disease (1-2 versus 3) disease were found to be significant factors for DFS. Univariate analysis also revealed the presence of cervical stromal involvement and grade of the disease were associated with decreased OS. In the multivariate analysis, however, only patients with an advanced histological grade had a reduced risk for OS (hazard ratio [HR] 2.9; 95% confidence interval [CI] 1.020-8.615; p= 0.040). In conclusion, histological grade seems to be an independent prognostic factor for OS in patients with Stage IIIA ECCs.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |